RHOD and lung carcinoma: In A549 lung cancer and MRC‐5 noncancer cell lines, luteolin dose rate of 40 μM did not show any cytotoxic activity whereas different doses of luteolin at 20–40 μM markedly inhibited the cancer stages in dose dependent fashion such as diminished the activity of phosphorylated nonreceptor tyrosine kinase, Ras homolog gene family member A, Ras‐related C3 botulinum toxin substrate 1, phosphorylated focal adhesion kinase, and CDC protein 42 expressions (Masraksa et al. 2020).